Leerink, Gilead Sciences
Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...
Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October ...
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 21. David Risinger ...
On Tuesday, Schrodinger Inc (SDGR) stock saw a modest uptick, ending the day at $18.68 which represents a slight increase of $0.76 or 4.24% from the prior close of $17.92. The stock opened at $17.82 ...
Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for Biohaven in a report released ...
Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging ...
Leerink Swann Reiterates on Aegerion Pharmaceuticals as Weakness is Overdone UPDATE: Leerink Swann Initiates Coverage on WellPoint as There is Upside Amid the Winds of Change UPDATE: Leerink ...
Fintel reports that on October 16, 2024, Leerink Partners initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Outperform recommendation. As of September 25, 2024, the average one ...
Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback